A Study Of Oral GW572016 In Advanced Or Metastatic Non-Small Cell Lung Cancer

Part of paid clinical trials in Jasper, Alabama.

Sponsor
GlaxoSmithKline
Study ID
NCT00073008
Phase
PHASE2
Status
Terminated

Conditions

  • Lung Cancer, Non-Small Cell

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • GW572016 (lapatinib) — DRUG
    tyrosine kinase inhibitor

Study Details

This study was designed to evaluate and compare the efficacy of two dose schedules of an oral investigational drug for the treatment of advanced or metastatic non-small cell lung cancer.

Key Dates

Start date
Nov 30, 2003
Status verified
Jan 2017
Primary completion
Jul 31, 2008
Completion
Jul 31, 2008

Study Design

Enrollment
131 participants (actual)
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Other: lapatinib
    Randomized, open-label, parallel group, 2-stage study to evaluate and compare 2 dose schedules (1500 mg once daily and 500 mg twice daily) of oral lapatinib.

Primary Outcome Measure

Tumor Response in the Targeted Population Through the End of Treatment [ Time Frame: Baseline and then every 8 weeks through end of treatment ]

Locations (23)

FacilityCityStateZIPSite coordinators
GSK Investigational SiteJasperAlabama35501-
GSK Investigational SiteGreenbraeCalifornia94904-2007-
GSK Investigational SiteLa JollaCalifornia92037-
GSK Investigational SiteLong BeachCalifornia90813-
GSK Investigational SitePowayCalifornia92064-
GSK Investigational SiteRancho MirageCalifornia92270-
GSK Investigational SiteWashington D.C.District of Columbia20007-
GSK Investigational SiteGainsvilleFlorida32610-
GSK Investigational SiteElk Grove VillageIllinois60007-
GSK Investigational SiteHoumaLouisiana70360-
GSK Investigational SiteMetairieLouisiana70006-
GSK Investigational SiteLebanonNew Hampshire03756-
GSK Investigational SiteNew BrunswickNew Jersey08901-
GSK Investigational SiteSanta FeNew Mexico87505-
GSK Investigational SiteNyackNew York10960-
GSK Investigational SiteChapel HillNorth Carolina27599-7600-
GSK Investigational SiteDurhamNorth Carolina27707-
GSK Investigational SiteClevelandOhio44106-
GSK Investigational SitePortlandOregon97213-
GSK Investigational SitePhiladelphiaPennsylvania19140-
GSK Investigational SiteNashvilleTennessee37203-
GSK Investigational SiteCorpus ChristiTexas78412-
GSK Investigational SiteHoustonTexas77030-

Find similar trials in Jasper, AL

By research site
GSK Investigational Site· Jasper, ALGSK Investigational Site· Greenbrae, CAGSK Investigational Site· La Jolla, CAGSK Investigational Site· Long Beach, CAGSK Investigational Site· Poway, CAGSK Investigational Site· Rancho Mirage, CA

Related Studies